enGene Therapeutics Inc.
ENGN- 1D
- -8.2%
enGene Therapeutics Inc. in brief
enGene Therapeutics Inc. is a listed company in the Biotechnology industry, based in Canada. Its market value was $105 M on 15 October 2026, which makes it the 18,572nd largest listed company in the world and the 694th largest in Canada on this site. It employs about 82 people. Its shares trade under the symbol ENGN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About enGene Therapeutics Inc.
enGene Holdings Inc. formed in connection with the Merger Agreement (as defined below), was incorporated as 14963148 Canada Inc. under the federal laws of Canada on April 24, 2023 and changed its name to enGene Holdings Inc. on May 9, 2023. On October 31, 2023, enGene Holdings Inc. continued from being a corporation incorporated under and governed by the Canada Business Corporations Act to a company continued to and governed by the Business Corporations Act (British Columbia).
Forbion European Acquisition Corporation was a special purpose acquisition company, incorporated as a Cayman Island exempted company on August 9, 2021 and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more business or entities. On October 31, 2023, the Company, FEAC, and enGene Inc., a subsidiary of the Company, consummated the merger pursuant to a business combination agreement, dated as of May 16, 2023.
From the company's annual report filed with the US SEC: read the report
enGene Therapeutics Inc. timeline
- 2022
- 🔔· approximateInitial public offering on Nasdaq
- 2023
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2026
- ✎Renamed enGene Therapeutics Inc.Formerly enGene Holdings Inc..
Events of enGene Therapeutics Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Canada: #504 (Aug 2026) · #699 (Oct 2026) · #694 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.6×
- Free cash flow yield
- -96.3%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -69.9%
- Liabilities / assets
- 24.3%
- Payout ratio
- 0.0%
- Profit per employee
- $-1.4 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Oct 2025 | — | — | $-123M | $-117M | — |
| Oct 2024 | — | — | $-62M | $-55M | — |
| Oct 2023 | — | — | $-26M | $-100M | — |
| Oct 2022 | — | — | $-19M | $-24M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Oct 2025 | $-99M | $1M | $-101M | $2.29 | $0.00 |
| Oct 2024 | $-48M | $1M | $-49M | $1.46 | $0.00 |
| Oct 2023 | $-25M | $0M | $-25M | $151.22 | $0.00 |
| Oct 2022 | $-18M | $0M | $-18M | $44.30 | — |
Quarterly results
Latest quarter to Jul 2026: revenue —, net income $-33M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jul 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure · Other events
- Sep 8, 202610-QQuarterly report · period to Jul 2026
- Sep 8, 20268-KCurrent reportResults of operations
- Aug 11, 20268-KCurrent reportOther events
- Jul 17, 20268-KCurrent reportRegulation FD disclosure
- Jul 16, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Jun 18, 20268-K/ACurrent report (amended)Restructuring costs · Directors or officers changed
- Jun 15, 202610-QQuarterly report · period to Apr 2026
- Jun 15, 20268-KCurrent reportResults of operations · Restructuring costs · Directors or officers changed · Regulation FD disclosure · Other events
- Jun 10, 20268-KCurrent reportShareholder vote
- May 8, 2026DEF 14AProxy statement
- May 7, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure · Other events
Official filings of enGene Therapeutics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-123 M
- Net income
- $-117 M
For year ending October-2025 · source: SEC filing
Balance sheet
- Total assets
- $221 M
- Total liabilities
- $54 M
- Total equity
- $168 M
As of October-2025
Top 58 institutional investors in enGene Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BML Capital Management, LLC | 6,669,908 | 0 (0.00%) | 9.95% | $13 M | Nov 6, 2026 |
| 2 | Siren, L.L.C. | 6,256,662 | 0 (0.00%) | 9.34% | $13 M | Nov 12, 2026 |
| 3 | Acorn Capital Advisors, LLC | 3,811,782 | +2,540,525 (+199.84%) | 5.69% | $8 M | Nov 16, 2026 |
| 4 | Perceptive Advisors LLC | 3,482,169 | -1,340,000 (-27.79%) | 5.20% | $7 M | Nov 16, 2026 |
| 5 | Eventide Asset Management, LLC | 3,406,023 | New | 5.08% | $7 M | Nov 13, 2026 |
| 6 | Nextech Invest Ltd. | 2,324,943 | 0 (0.00%) | 3.47% | $5 M | Nov 16, 2026 |
| 7 | Vestal Point Capital, LP | 1,665,000 | -2,430 (-0.15%) | 2.48% | $3 M | Nov 16, 2026 |
| 8 | ADAR1 Capital Management, LLC | 1,329,986 | -775,000 (-36.82%) | 1.98% | $3 M | Nov 16, 2026 |
| 9 | Two Sigma Investments, LP | 1,292,137 | +1,127,567 (+685.16%) | 1.93% | $3 M | Nov 16, 2026 |
| 10 | Renaissance Technologies LLC | 1,134,400 | +304,700 (+36.72%) | 1.69% | $2 M | Nov 12, 2026 |
| 11 | Peapod Lane Capital LLC | 1,038,617 | -63,532 (-5.76%) | 1.55% | $2 M | Oct 22, 2026 |
| 12 | SR One Capital Management, LP | 747,750 | New | 1.12% | $1 M | Nov 16, 2026 |
| 13 | Aldebaran Capital, LLC | 657,319 | New | 0.98% | $1 M | Nov 13, 2026 |
| 14 | Flputnam Investment Management Co | 556,121 | New | 0.83% | $1 M | Nov 13, 2026 |
| 15 | Kynam Capital Management, LP | 457,855 | 0 (0.00%) | 0.68% | $1 M | Nov 16, 2026 |
| 16 | Citadel Advisors LLC | 444,471 | -273,215 (-38.07%) | 0.66% | $1 M | Nov 16, 2026 |
| 17 | Squarepoint Ops LLC | 299,747 | +84,366 (+39.17%) | 0.45% | $1 M | Nov 9, 2026 |
| 18 | Jane Street Group, LLC | 291,730 | -90,729 (-23.72%) | 0.44% | $1 M | Nov 12, 2026 |
| 19 | Rangeley Capital, LLC | 287,898 | -17,204 (-5.64%) | 0.43% | $1 M | Nov 16, 2026 |
| 20 | Millennium Management LLC | 181,619 | -785,008 (-81.21%) | 0.27% | $0 M | Nov 16, 2026 |
| 21 | D. E. Shaw & Co., Inc. | 170,408 | New | 0.25% | $0 M | Nov 16, 2026 |
| 22 | Privium Fund Management B.V. | 170,000 | 0 (0.00%) | 0.25% | $0 M | Nov 3, 2026 |
| 23 | Gsa Capital Partners LLP | 127,975 | +90,629 (+242.67%) | 0.19% | $0 M | Nov 16, 2026 |
| 24 | XTX Topco Ltd | 117,582 | -33,842 (-22.35%) | 0.18% | $0 M | Nov 16, 2026 |
| 25 | Quadrature Capital Ltd | 100,069 | -138,966 (-58.14%) | 0.15% | $0 M | Nov 13, 2026 |
Show all 58: investors 26 to 58
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Point72 Asset Management, L.P. | 75,552 | +61,560 (+439.97%) | 0.11% | $0 M | Nov 16, 2026 |
| 27 | DAFNA Capital Management LLC | 74,650 | 0 (0.00%) | 0.11% | $0 M | Nov 16, 2026 |
| 28 | HRT Financial LP | 74,395 | +57,564 (+342.01%) | 0.11% | $0 M | Nov 13, 2026 |
| 29 | Carlson Capital, L.P. | 50,000 | New | 0.07% | $0 M | Nov 9, 2026 |
| 30 | Axq Capital, LP | 49,869 | New | 0.07% | $0 M | Nov 12, 2026 |
| 31 | PFS Partners, LLC | 40,000 | +29,000 (+263.64%) | 0.06% | $0 M | Oct 21, 2026 |
| 32 | Engineers Gate Manager LP | 39,522 | +12,236 (+44.84%) | 0.06% | $0 M | Nov 16, 2026 |
| 33 | Dimensional Fund Advisors LP | 38,291 | 0 (0.00%) | 0.06% | $0 M | Nov 4, 2026 |
| 34 | Marshall Wace, LLP | 35,982 | New | 0.05% | $0 M | Nov 13, 2026 |
| 35 | Spark Investment Management LLC | 30,800 | New | 0.05% | $0 M | Nov 13, 2026 |
| 36 | Indivisible Partners | 29,446 | New | 0.04% | $0 M | Oct 26, 2026 |
| 37 | Scientech Research LLC | 29,004 | -11,706 (-28.75%) | 0.04% | $0 M | Nov 16, 2026 |
| 38 | Sectoral Asset Management Inc | 21,700 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 39 | Morgan Stanley | 21,685 | -11,401 (-34.46%) | 0.03% | $0 M | Nov 13, 2026 |
| 40 | Covestor Ltd | 21,451 | New | 0.03% | $0 M | Oct 30, 2026 |
| 41 | BNP Paribas Financial Markets | 20,486 | -4,933 (-19.41%) | 0.03% | $0 M | Nov 12, 2026 |
| 42 | Graham Capital Management, L.P. | 19,933 | New | 0.03% | $0 M | Nov 16, 2026 |
| 43 | Susquehanna International Group, LLP | 17,743 | -6,727 (-27.49%) | 0.03% | $0 M | Nov 16, 2026 |
| 44 | Jpmorgan Chase & Co | 15,556 | New | 0.02% | $0 M | Nov 12, 2026 |
| 45 | Obsidian Cio, LLC | 15,000 | New | 0.02% | $0 M | Nov 5, 2026 |
| 46 | Virtu Financial LLC | 14,031 | +45 (+0.32%) | 0.02% | $0 M | Nov 17, 2026 |
| 47 | Royal Bank Of Canada | 11,325 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 48 | Raymond James Financial Inc | 11,284 | -10,072 (-47.16%) | 0.02% | $0 M | Nov 12, 2026 |
| 49 | Wells Fargo & Company/mn | 6,840 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 50 | UBS Group AG | 6,518 | -502,569 (-98.72%) | 0.01% | $0 M | Nov 10, 2026 |
| 51 | Simplex Trading, LLC | 5,025 | +4,626 (+1159.40%) | 0.01% | $0 M | Nov 4, 2026 |
| 52 | Citigroup Inc | 492 | New | 0.00% | $0 M | Nov 4, 2026 |
| 53 | Wolverine Asset Management LLC | 278 | -2,686 (-90.62%) | 0.00% | $0 M | Nov 2, 2026 |
| 54 | Tower Research Capital LLC (TRC) | 233 | New | 0.00% | $0 M | Nov 16, 2026 |
| 55 | Group One Trading LLC | 215 | New | 0.00% | $0 M | Nov 10, 2026 |
| 56 | Farther Finance Advisors, LLC | 100 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 57 | SBI Securities Co., Ltd. | 28 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 58 | Aquatic Capital Management LLC | 21 | -8 (-27.59%) | 0.00% | $0 M | Nov 16, 2026 |
Mutual funds holding enGene Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 40,733 | $0 M | — | <0.01% | +5.0% | May 31, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 10,639 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 9,974 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 1,376 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at enGene Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | William GrossmanInterim Chief Medical Officer, Director | Buy | +5,102 | $1.970 | $10 K | 5,102 | Form 4 |
| filed | Forbion Growth Management B.V.10% owner | Buy | +561,797 | $8.900 | $5.0 M | 3.03 M | Form 4 |
| filed | Forbion Growth Opportunities Fund I Cooperatief U.A.10% owner | Buy | +800 | $6.600 | $5 K | 2.47 M | Form 4 |
| filed | Forbion Growth Opportunities Fund I Cooperatief U.A.10% owner | Buy | +11,844 | $6.550 | $78 K | 2.47 M | Form 4 |
| filed | Forbion Growth Opportunities Fund I Cooperatief U.A.10% owner | Buy | +5,997 | $6.540 | $39 K | 2.46 M | Form 4 |
| filed | Forbion Growth Opportunities Fund I Cooperatief U.A.10% owner | Buy | +5,769 | $6.480 | $37 K | 2.45 M | Form 4 |
| filed | Forbion Growth Opportunities Fund I Cooperatief U.A.10% owner | Buy | +10,153 | $6.370 | $65 K | 2.45 M | Form 4 |
| filed | Forbion Growth Opportunities Fund I Cooperatief U.A.10% owner | Buy | +35,279 | $6.440 | $227 K | 2.44 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: enGene Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-5.54 reverse split
| Dividend, quarter | Per share | |
|---|---|---|
| Q1 2026 | $0.000 | |
| Q1 2025 | $0.000 | |
| Q1 2024 | $0.000 |
Trading halts
- 2025-11-11 15:08 UTC, code LUDP, resumed 15:13 UTC
- 2025-11-11 15:02 UTC, code LUDP, resumed 15:07 UTC
Fails to deliver
- : 9,142 shares at $1.56
- : 75 shares at $1.70
- : 4,517 shares at $1.78
- : 6,255 shares at $1.75
- : 1,738 shares at $1.80
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
enGene Therapeutics Inc. scorecard#
Passes 3 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Oct 15, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-96.3%Free cash flow is -96.3% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✓Earnings per share grew in the newest year2.29 vs 1.46Diluted EPS 2.29 in fiscal 2025 against 1.46 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$117 MNet income -$117 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-53.3%-53.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities6.3×Current ratio 6.30 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 2
- ✗Pays a dividendNoNo dividends in fiscal 2025.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year35.3%Diluted shares up 35.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
enGene Therapeutics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Oct 31, 2025 | FY 2024to Oct 31, 2024 | FY 2023to Oct 31, 2023 | FY 2022to Oct 31, 2022 |
|---|---|---|---|---|---|
| Income statement | |||||
| Research and development | 94+147%— | 38+133%— | 16+6.4%— | 15—— | |
| General and administrative | 29+19.6%— | 24+150%— | 9.6+142%— | 4.0—— | |
| Operating expenses | 123+97.7%— | 62+139%— | 26+34.1%— | 19—— | |
| Operating income | −123—— | −62—— | −26—— | −19—— | |
| Interest and finance income | 9.4−9.5%— | 10+832%— | 1.1+766%— | 0.1—— | |
| Interest expense and finance costs | 3.0+7.0%— | 2.8−43.5%— | 5.0+248%— | 1.4—— | |
| Other non-operating income (expense) | 5.9−17.8%— | 7.1—— | −74—— | −5.0—— | |
| Income before tax | −117—— | −55—— | −100—— | −24—— | |
| Income tax | 0—— | −0.0−212%— | 0.0−22.7%— | 0.0—— | |
| Net income including minority interests | −117—— | −55—— | −100—— | −24—— | |
| Net income attributable to shareholders | −117—— | −55—— | −100—— | −24—— | |
| Earnings per share, basic | 2.29+56.8%— | 1.46−99.0%— | 151.22+241%— | 44.30—— | |
| Earnings per share, diluted | 2.29+56.8%— | 1.46−99.0%— | 151.22+241%— | 44.30—— | |
| Shares, weighted average (basic) | 51+35.3%— | 38+5355%— | 0.7+5.7%— | 0.7—— | |
| Shares, weighted average (diluted) | 51+35.3%— | 38+5355%— | 0.7+5.7%— | 0.7—— | |
| Dividends per share | 0.00—— | 0.00—— | 0.00—— | — | |
| Balance sheet | |||||
| Cash and cash equivalents | 50−71.0%22.6% | 173+112%55.6% | 82+299%93.7% | 20—85.5% | |
| Short-term investments | 144+120%64.8% | 65—21.0% | — | — | |
| Other current assets | 6.6−22.9%3.0% | 8.6+475%2.8% | 1.5+103%1.7% | 0.7—3.1% | |
| Current assets | 201−18.6%90.9% | 247+190%79.5% | 85+278%98.3% | 23—94.5% | |
| Property, plant and equipment | 2.5+112%1.1% | 1.2+98.5%0.4% | 0.6+52.2%0.7% | 0.4—1.6% | |
| Right-of-use (leased) assets | 7.7+343%3.5% | 1.7—0.6% | — | — | |
| Total assets | 221−28.8%100% | 311+258%100% | 87+264%100% | 24—100% | |
| Accounts payable | 6.7+374%3.0% | 1.4+22.1%0.5% | 1.2+59.9%1.3% | 0.7—3.0% | |
| Current liabilities | 32+118%14.4% | 15+179%4.7% | 5.3+3.0%6.0% | 5.1—21.3% | |
| Lease liabilities (non-current) | 6.5+352%2.9% | 1.4—0.5% | — | — | |
| Total liabilities | 54+39.4%24.3% | 39+166%12.4% | 14−69.5%16.6% | 47—198% | |
| Retained earnings | −372—−168% | −255—−81.9% | −200—−230% | −100—−417% | |
| Shareholders' equity | 168−38.5%75.7% | 273+276%87.6% | 72—83.4% | −77—−320% | |
| Total liabilities and equity | 221−28.8%100% | 311+258%100% | 87+264%100% | 24—100% | |
| Shares outstanding | 52+2.0%— | 51+120%— | 23+3384%— | 0.7—— | |
| Cash-flow statement | |||||
| Depreciation and amortization | 0.5+66.7%— | 0.3+50.0%— | 0.20.0%— | 0.2—— | |
| Share-based compensation | 9.6+81.2%— | 5.3+54.3%— | 3.5+2874%— | 0.1—— | |
| Cash from operating activities | −99—— | −48—— | −25—— | −18—— | |
| Capital expenditure | −1.5—— | −0.9—— | −0.3—— | −0.2—— | |
| Cash from investing activities | −25—— | −126—— | −0.3—— | −0.2—— | |
| Debt issued | — | 23—— | — | 11—— | |
| Debt repaid | — | — | — | −1.0—— | |
| Dividends paid | — | — | 0—— | — | |
| Cash from financing activities | 1.5−99.4%— | 266+208%— | 86+208%— | 28—— | |
| Exchange-rate effect on cash | 0.00.0%— | 0.00.0%— | 0.0—— | −0.8—— | |
| Change in cash | −123−234%— | 91+49.8%— | 61+549%— | 9.4—— | |
| Report | 10-K | 10-K | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jul 31, 2026 | Q3 FY2026to Jul 31, 2026 | Q2 FY2026to Apr 30, 2026 | Q1 FY2026to Jan 31, 2026 | Q4 FY2025to Oct 31, 2025 | Q3 FY2025to Jul 31, 2025 | Q2 FY2025to Apr 30, 2025 | Q1 FY2025to Jan 31, 2025 | Q4 FY2024to Oct 31, 2024 | Q3 FY2024to Jul 31, 2024 | Q2 FY2024to Apr 30, 2024 | Q1 FY2024to Jan 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Research and development | 96+30.0%— | 20−11.0%— | 22+9.8%— | 22+11.4%— | 32*+181%— | 23+95.5%— | 20+105%— | 20+254%— | 11*—— | 12—— | 9.9—— | 5.6—— | |
| General and administrative | 40+49.0%— | 14+88.9%— | 9.8+41.3%— | 8.9+34.5%— | 7.8*+25.5%— | 7.4+41.5%— | 6.9−7.2%— | 6.6+29.3%— | 6.2*—— | 5.2—— | 7.5—— | 5.1—— | |
| Operating expenses | 137+35.1%— | 34+13.6%— | 32+17.9%— | 31+17.2%— | 39*+126%— | 30+78.7%— | 27+56.7%— | 27+147%— | 17*—— | 17—— | 17—— | 11—— | |
| Operating income | −137—— | −34—— | −32—— | −31—— | −39*—— | −30—— | −27—— | −27—— | −17*—— | −17—— | −17—— | −11—— | |
| Interest and finance income | 9.8−6.6%— | 2.4+7.5%— | 2.7+7.0%— | 2.7+0.4%— | 2.0*−34.7%— | 2.2−33.9%— | 2.5−16.6%— | 2.7+166%— | 3.0*—— | 3.4—— | 3.0—— | 1.0—— | |
| Interest expense and finance costs | 3.1+2.3%— | 0.8+11.2%— | 0.7+1.5%— | 0.7−2.7%— | 0.8*−0.8%— | 0.8+0.9%— | 0.7+0.8%— | 0.8+33.6%— | 0.8*—— | 0.8—— | 0.7—— | 0.6—— | |
| Other non-operating income (expense) | 5.8−16.5%— | 1.5+26.6%— | 1.7+12.4%— | 1.4−28.9%— | 1.1*−49.2%— | 1.2−53.7%— | 1.5−34.0%— | 2.0+6197%— | 2.2*—— | 2.6—— | 2.3—— | 0.0—— | |
| Income before tax | −131—— | −33—— | −30—— | −30—— | −38*—— | −29—— | −26—— | −25—— | −15*—— | −14—— | −15—— | −11—— | |
| Income tax | −0.5−196%— | 0−100%— | 0−100%— | 0−100%— | −0.5*−2716%— | 0.2—— | 0.2+1043%— | 0.0—— | 0.0*—— | −0.0—— | 0.0—— | −0.0—— | |
| Net income including minority interests | −130—— | −33*—— | −30*—— | −30—— | −38*—— | −29*—— | −26*—— | −25—— | −15*—— | −14*—— | −15*—— | −11—— | |
| Net income attributable to shareholders | −130—— | −33—— | −30—— | −30—— | −38*—— | −29—— | −26—— | −25—— | −15*—— | −14—— | −15—— | −11—— | |
| Earnings per share, basic | — | -0.47—— | -0.43—— | 0.44−8.3%— | — | -0.57r0.57−278%— | -0.51r0.51−234%— | 0.48+4.3%— | — | 0.32—— | 0.38—— | 0.46—— | |
| Earnings per share, diluted | — | -0.47—— | -0.43—— | 0.44−8.3%— | — | -0.57r0.57−278%— | -0.51r0.51−234%— | 0.48+4.3%— | — | 0.32—— | 0.38—— | 0.46—— | |
| Shares, weighted average (basic) | 70+36.5%— | 70+36.5%— | 70+36.7%— | 67+31.9%— | — | 51+15.7%— | 51+29.3%— | 51+120%— | — | 44—— | 39—— | 23—— | |
| Shares, weighted average (diluted) | 70+36.5%— | 70+36.5%— | 70+36.7%— | 67+31.9%— | — | 51+15.7%— | 51+29.3%— | 51+120%— | — | 44—— | 39—— | 23—— | |
| Dividends per share | — | — | — | 0.00—— | — | — | — | 0.00—— | — | — | — | 0.00—— | |
| Balance sheet | |||||||||||||
| Cash and cash equivalents | 41—14.2% | 41+25.8%14.2% | 30−48.2%9.7% | 37−41.3%10.9% | 50−71.0%22.6% | 33−87.3%13.3% | 58−78.3%21.6% | 62−27.2%21.8% | 173—55.6% | 258—96.6% | 265—96.8% | 86—91.7% | |
| Short-term investments | 225—78.1% | 225+33.1%78.1% | 229+43.0%74.3% | 239+58.0%71.0% | 144+120%64.8% | 169—68.9% | 160—59.9% | 151—53.0% | 65—21.0% | — | — | — | |
| Other current assets | 11—3.7% | 11+22.1%3.7% | 11+6.6%3.5% | 12+49.9%3.6% | 6.6−22.9%3.0% | 8.6+83.4%3.5% | 10.0+184%3.7% | 8.0+194%2.8% | 8.6—2.8% | 4.7—1.8% | 3.5—1.3% | 2.7—2.9% | |
| Current assets | 278—96.4% | 278+31.5%96.4% | 270+18.4%87.8% | 289+30.1%85.8% | 201−18.6%90.9% | 211−19.6%86.1% | 228−15.4%85.5% | 222+148%77.8% | 247—79.5% | 263—98.4% | 270—98.6% | 90—95.9% | |
| Property, plant and equipment | 2.2—0.7% | 2.2+14.7%0.7% | 2.3+50.4%0.8% | 2.4+78.7%0.7% | 2.5+112%1.1% | 1.9+85.3%0.8% | 1.6+40.3%0.6% | 1.4+37.6%0.5% | 1.2—0.4% | 1.0—0.4% | 1.1—0.4% | 1.0—1.1% | |
| Right-of-use (leased) assets | 6.9—2.4% | 6.9−13.7%2.4% | 7.1+333%2.3% | 7.5+342%2.2% | 7.7+343%3.5% | 8.0+345%3.2% | 1.6−10.7%0.6% | 1.7−9.9%0.6% | 1.7—0.6% | 1.8—0.7% | 1.8—0.7% | 1.9—2.0% | |
| Total assets | 288—100% | 288+17.4%100% | 308+15.3%100% | 337+17.9%100% | 221−28.8%100% | 246−8.0%100% | 267−2.5%100% | 286+206%100% | 311—100% | 267—100% | 274—100% | 93—100% | |
| Accounts payable | 2.5—0.9% | 2.5+6.6%0.9% | 1.8+14.4%0.6% | 2.4−6.5%0.7% | 6.7+374%3.0% | 2.4−16.7%1.0% | 1.6+643%0.6% | 2.6+104%0.9% | 1.4—0.5% | 2.9—1.1% | 0.2—0.1% | 1.3—1.4% | |
| Current liabilities | 27—9.4% | 27+33.1%9.4% | 21+19.4%7.0% | 25+90.0%7.3% | 32+118%14.4% | 20+51.9%8.3% | 18+186%6.8% | 13+87.6%4.5% | 15—4.7% | 13—5.0% | 6.3—2.3% | 6.9—7.4% | |
| Lease liabilities (non-current) | 5.7—2.0% | 5.7−15.8%2.0% | 6.0+346%1.9% | 6.2+367%1.8% | 6.5+352%2.9% | 6.7+355%2.7% | 1.3−12.9%0.5% | 1.3−16.9%0.5% | 1.4—0.5% | 1.5—0.6% | 1.5—0.6% | 1.6—1.7% | |
| Total liabilities | 58—20.1% | 58+29.3%20.1% | 52+33.0%17.0% | 56+54.4%16.5% | 54+39.4%24.3% | 45+22.8%18.3% | 39+28.8%14.8% | 36+15.9%12.6% | 39—12.4% | 37—13.7% | 31—11.2% | 31—33.2% | |
| Retained earnings | −465—−161% | −465—−161% | −432—−140% | −402—−119% | −372—−168% | −334—−136% | −305—−114% | −279—−97.7% | −255—−81.9% | −239—−89.7% | −225—−82.4% | −210—−225% | |
| Shareholders' equity | 230—79.9% | 230+14.8%79.9% | 255+12.3%83.0% | 282+12.6%83.5% | 168−38.5%75.7% | 201−12.9%81.7% | 227−6.5%85.2% | 250+301%87.4% | 273—87.6% | 230—86.3% | 243—88.8% | 62—66.8% | |
| Total liabilities and equity | 288—100% | 288+17.4%100% | 308+15.3%100% | 337+17.9%100% | 221−28.8%100% | 246−8.0%100% | 267−2.5%100% | 286+206%100% | 311—100% | 267—100% | 274—100% | 93—100% | |
| Shares outstanding | 67—— | 67+31.1%— | 67+31.2%— | 67+31.4%— | 52+2.0%— | 51+15.6%— | 51+15.7%— | 51+120%— | 51—— | 44—— | 44—— | 23—— | |
| Cash-flow statement | |||||||||||||
| Depreciation and amortization | 0.7+71.4%— | 0.10.0%— | 0.2+100%— | 0.2+85.3%— | 0.2*+100%— | 0.10.0%— | 0.10.0%— | 0.1+27.5%— | 0.1r0.1*—— | 0.1r0.1—— | 0.1r0.1—— | 0.1—— | |
| Share-based compensation | 17+99.7%— | 7.8+203%— | 4.1+56.4%— | 2.8+54.9%— | 2.6*+57.4%— | 2.6+76.8%— | 2.7+38.2%— | 1.8+522%— | 1.7*—— | 1.5—— | 1.9—— | 0.3—— | |
| Cash from operating activities | −103—— | −19*—— | −30*—— | −29—— | −25*—— | −26*—— | −23*—— | −26—— | −20*—— | −7.2*—— | −14*—— | −7.4—— | |
| Capital expenditure | −0.7—— | 0*—— | −0.1*—— | −0.2—— | −0.4*—— | −0.7*—— | −0.0*—— | −0.3—— | −0.2*—— | −0.0*—— | −0.2*—— | −0.5—— | |
| Cash from investing activities | −32—— | 30*+2084%— | 24*+31.7%— | −126—— | 41*—— | 1.4*—— | 18*—— | −85—— | −125*—— | −0.0*—— | −0.2*—— | −0.5—— | |
| Debt issued | — | 0*—— | 0*—— | 25—— | — | — | — | — | 0*—— | 0*—— | 0*—— | 23—— | |
| Cash from financing activities | 144+141%— | 0.0*—— | 0.1*−62.8%— | 142+14165900%— | 2.0*−96.7%— | −0.7*−1408%— | 0.2*−99.9%— | 0.0−100.0%— | 60*—— | 0.1*—— | 194*—— | 12—— | |
| Exchange-rate effect on cash | 0.00.0%— | 0*—— | 0*—— | 0.00.0%— | 0*—— | 0*—— | 0*—— | 0.00.0%— | 0*—— | 0*—— | 0*—— | 0.0—— | |
| Change in cash | 8.4—— | 11*—— | −6.8*—— | −14—— | 18*—— | −25*—— | −4.8*−103%— | −111−2783%— | −85*—— | −7.1*—— | 179*—— | 4.1—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jul 31, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at enGene Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 2 · Directors and officers 9 · Material agreement 5 · Agreement ended 1 · New debt 2 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| RestructuringDirectors and officers | 8-K/A | |
| RestructuringDirectors and officersResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K/A | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 50% of workforce | Restructuring planSEC 8-K | “As previously disclosed in the Company’s Original Form 8-K, effective June 14, 2026, the Company’s board of directors (the “Board”) approved a plan to reduce the Company’s workforc…” | Filing | |
| 50% of workforce | Restructuring planSEC 8-K | “On June 15, 2026, the Company announced the implementation of a plan to reduce its workforce by approximately 50% to streamline operations and preserve cash.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How enGene Therapeutics Inc. compares in Biotechnology
- Market cap$105 M · higher than 37% of 726
- Price / book0.6× · lower than 89% of 534
- FCF yield-96.3% · higher than 10% of 449
- 🇺🇸 Unicycive Therapeutics, Inc.$105 M
- 🇮🇱 PolyPid Ltd.$103 M
- 🇺🇸 vTv Therapeutics Inc.$103 M
- 🇺🇸 Rafael Holdings, Inc.$103 M
- 🇺🇸 Equillium, Inc.$103 M
- 🇺🇸 OnKure Therapeutics, Inc.$107 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| enGene Therapeutics Inc.🇨🇦 | $105 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 15, 2026
- Annual results:
- For year ending October-2025
- Balance sheet:
- As of October-2025
- Employees:
- As of October 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at enGene Therapeutics Inc.? Verify and update this profile — free
Show enGene Therapeutics Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.